Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.

Valeria Santini, Thomas Prebet, Pierre Fenaux, Norbert Gattermann, Lars Nilsson, Michael Pfeilstöcker, Paresh Vyas, Alan F List

    Research output: Contribution to journalReview articlepeer-review

    25 Citations (SciVal)

    Abstract

    In Europe, azacitidine is the only hypomethylating agent approved for the treatment of patients with int-2-/high-risk myelodysplastic syndromes, offering significantly improved survival compared with conventional care. However, not all patients treated with azacitidine respond to treatment, and the vast majority of responders subsequently relapse. Currently, no standard care regimens have been established for patients after failure of azacitidine. Here, we discuss treatment options after loss of response or progression on azacitidine. In addition, we briefly consider optimization of first-line treatment along with potential biomarkers for identifying and monitoring response during treatment with azacitidine.
    Original languageEnglish
    Pages (from-to)1381-1391
    JournalLeukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis
    Volume38
    Issue number12
    DOIs
    Publication statusPublished - 2014

    Subject classification (UKÄ)

    • Cancer and Oncology

    Fingerprint

    Dive into the research topics of 'Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.'. Together they form a unique fingerprint.

    Cite this